No Data
Xiaofang Pharmaceutical (603207.SH): Granted 1.28 million shares of restricted Stocks to the incentive recipients.
On February 13, Gelonghui reported that Xiaofang Pharmaceutical (603207.SH) announced that the Board of Directors believes the conditions for granting restricted stocks under the 2025 Restricted Stock Incentive Plan (hereinafter referred to as "this incentive plan") have been met, determining the first grant date for this incentive plan to be February 13, 2025, agreeing to grant 1.28 million shares of restricted stocks to 178 incentive recipients at a grant price of 14.97 yuan per share.
Calculating The Fair Value Of Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHSE:603207)
Xiaofang Pharmaceutical (603207.SH): Plans to promote a restricted stock incentive plan of no more than 1.6 million shares.
On January 3, Glory Investment announced that Xiaofang Pharmaceutical (603207.SH) has unveiled a restrictive Stocks incentive plan for 2025, proposing a total of no more than 1.6 million Stocks to be granted, accounting for 1.00% of the company's total share capital of 160 million Stocks at the time of the announcement of the plan. The number of incentive recipients in the initial grant will not exceed 178 people, and the grant price of the initial restrictive Stocks is set at 14.97 yuan per share.
Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHSE:603207) Shares Fly 29% But Investors Aren't Buying For Growth
Xiaofang Pharmaceutical: Shanghai Xiaofang Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Shanghai Xiaofang Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024